At Frontiers Health 2025, Mike Ryan, General Manager Europe at EVERSANA, tackled one of the most pressing questions for ...

In the ATTAIN-MAINTAIN study of its orforglipron candidate, switching to the drug after 72 months of injectable treatment ...

BMS signed a multiyear agreement with antibody specialist Harbour BioMed, which has operations in the US, the Netherlands, ...

The ECDC warns of a ‘perfect storm’ and calls for innovation, including through the development of new medicines, enhanced ...

Daiichi Sankyo and AstraZeneca have pressed swiftly to file for approval of their TROP2-targeting drug Datroway for ...

The FDA’s emerging framework represents more than a regulatory update; it is a paradigm shift toward human-relevant, science-forward drug development. By reducing reliance on animal models and ...

Compared to Sotyktu (deucravacitinib), which was approved by the FDA for plaque psoriasis in 2022 and brought in sales of ...

According to Reuters, MSD – known as Merck & Co in the US and Canada – is set to be the recipient of the 17th and 18th ...

The UK has reached a critical inflection point in its digital journey. Over $40 billion in fresh commitments from global ...

The Women in AI Healthcare event series - hosted by Real Chemistry in collaboration with Pharma Brands – brings together ...

Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as a perioperative therapy for ...